Study comparing low-dose versus standard-dose epinephrine for better brain recovery in patients with out-of-hospital cardiac arrest

3 1 1 1

What is this study about?

This study focuses on patients who experience out-of-hospital cardiac arrest, a serious medical emergency that occurs when the heart suddenly stops beating outside of a hospital setting. The research examines the use of epinephrine, also known as adrenaline, which is a medication commonly used during cardiac emergencies to help restart the heart.

The purpose of this study is to compare two different doses of epinephrine in treating cardiac arrest patients. The study will test whether a lower dose (0.5 mg) works better than the standard dose (1 mg) in helping patients survive with good brain function. The medication will be given as a solution for injection through a vein during emergency treatment by medical teams.

During the study, patients will be randomly assigned to receive either the lower or standard dose of epinephrine. Neither the patients nor the medical team will know which dose is being given. The treatment will be provided as part of the emergency care when medical teams arrive to help someone experiencing cardiac arrest. The study will monitor how well patients recover over 28 days after their cardiac arrest.

1 Initial assessment

Medical team assesses the out-of-hospital cardiac arrest situation

Verification of basic eligibility: age 18 or older and presence of social security coverage

Confirmation that the cardiac arrest is medical in nature, not due to trauma or other causes

2 Emergency medication administration

You will receive either:

– A low dose of 0.5 mg epinephrine through intravenous injection, or

– A standard dose of 1.0 mg epinephrine through intravenous injection

The type of dose is randomly assigned and neither you nor the medical team will know which dose is being used

3 Immediate monitoring

Medical team checks for return of spontaneous circulation (return of pulse and blood pressure)

Continued monitoring during transport to hospital if circulation returns

4 Hospital admission assessment

Documentation of survival status upon hospital arrival

Initial medical evaluation and care at the hospital

5 28-day follow-up period

Assessment of survival status throughout the 28-day period

Evaluation of brain function using the Modified Rankin Scale (a measure of disability level)

Final assessment of recovery and neurological function at day 28

Who Can Join the Study?

  • Must be at least 18 years old
  • Can be either male or female
  • Must have experienced a cardiac arrest (when heart suddenly stops beating) outside of a hospital setting
  • The cardiac arrest must be due to medical causes
  • Must be receiving resuscitation efforts from the Mobile Medical Team (emergency medical services)
  • Must have active social security coverage or be a beneficiary of a social security plan

Who Cannot Join the Study?

  • Age under 18 years old
  • Pregnant women
  • Patients with a Do Not Resuscitate (DNR) order – this means they have previously stated they do not wish to receive resuscitation
  • Patients with traumatic cardiac arrest – when the heart stops due to physical injury
  • Patients with hypothermic cardiac arrest – when the heart stops due to very low body temperature
  • Patients who have already received epinephrine (adrenaline) before the arrival of the medical team
  • Patients whose cardiac arrest was not witnessed by anyone
  • Patients who did not receive immediate cardiopulmonary resuscitation (CPR) – chest compressions and rescue breaths
  • Patients with terminal illness
  • Patients participating in other clinical trials
  • Patients who cannot be followed up for 28 days after the cardiac arrest
  • Patients whose family members refuse consent for participation

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hopital Necker Enfants Malades Paris France
Centre Hospitalier Regional Et Universitaire De Brest Brest France
Oncopole Claudius Regaud Toulouse France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier De Colmar Colmar France
Centre Hospitalier Universitaire Rouen Rouen France
Centre Hospitalier Universitaire De Nimes Nimes France
Centre Hospitalier Universitaire De Poitiers Poitiers France
Hopital Beaujon Clichy France
Centre Hospitalier Sud Francilien Corbeil Essonnes France
Centre Hospitalier Universitaire De Montpellier Montpellier France
Centre Hospitalier De La Cote Basque Bayonne France
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Universitaire De Nice Nice France
Centre Hospitalier Universitaire De Rennes Rennes France
Centre Hospitalier Lyon Sud Pierre Benite France
Ciqnzk Hlfetrdbdiy Uvrkxqqnomlfg Rcpqt Reims France
Ctpawu hsykiykeypd Aqfzds Gbfxzwlv Styd Jwfmek eb Gvxvhbcp Saint-Julien-en-Genevois France
Bgadmxw dq Slnnmpumwsmcglhg dd Pnsoj Courbevoie France
Cum dtzvlevaeyemgr Epagny Metz Tessy France
Bbnllqzu Umjgszpwym Hskbfdds Cfwzxf Besançon France
Cjfhhm Hjnnhyhiieg Rllwvvdv Uccerukxkbxvx Dp Tiell Tours France
Cebk Df Nrxtu Vandoeuvre Les Nancy France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
01.12.2025

Trial locations

Investigated drugs:

Epinephrine (also known as adrenaline) is a medication used during cardiac arrest to help restart the heart. It works by increasing blood pressure and heart contrraction strength. In this trial, researchers are studying how different amounts of epinephrine might affect brain function in patients who experience cardiac arrest outside of the hospital. This medication is typically given through an injection directly into the bloodstream by emergency medical personnel when someone’s heart stops beating.

Investigated diseases:

Out-of-hospital cardiac arrest – A sudden loss of heart function that occurs outside of a hospital setting. It happens when the heart’s electrical system malfunctions and the heart stops beating effectively, causing the person to lose consciousness and stop breathing normally. During cardiac arrest, blood flow to vital organs ceases, particularly affecting the brain and other critical systems. The condition develops suddenly and requires immediate emergency response. The heart’s normal rhythm can be disrupted by various underlying causes, including heart disease, electrical disturbances, or other medical conditions.

Trial ID:
2023-505349-26-00
Protocol code:
2021PI170
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on Levosimendan for Improving Survival in Patients with Out-of-Hospital Cardiac Arrest During CPR

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden
  • Study of anti-seizure drug combination in comatose patients with status epilepticus after cardiac arrest

    Recruiting

    3 1 1 1
    Investigated diseases:
    Belgium The Netherlands